Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Investing Activities (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Cash from Investing Activities data on record, last reported at $13.2 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 40.64% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $112.0 million, up 474.67%, while the annual FY2025 figure was $112.0 million, 474.67% up from the prior year.
  • Cash from Investing Activities reached $13.2 million in Q4 2025 per FHTX's latest filing, down from $35.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $77.1 million in Q2 2021 and bottomed at -$159.4 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is $921850.0, with a median of $24.7 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: surged 3529.23% in 2021, then tumbled 4788.35% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $9.7 million in 2021, then crashed by 167.27% to -$6.5 million in 2022, then skyrocketed by 674.54% to $37.4 million in 2023, then tumbled by 40.37% to $22.3 million in 2024, then crashed by 40.64% to $13.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $13.2 million in Q4 2025, $35.6 million in Q3 2025, and $33.8 million in Q2 2025.